| Similar Articles |
|---|
 |
The Motley Fool
December 23, 2011
Selena Maranjian |
3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick.   |
The Motley Fool
July 29, 2011
Sean Williams |
Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling. |
The Motley Fool
August 15, 2011
Jim Royal |
6 Wild Bets on Biotech Riches The most interesting biotech tickers. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
BusinessWeek
May 28, 2009
Catherine Arnst |
Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs. |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
The Motley Fool
September 27, 2006
Brian Lawler |
One Step Forward for InterMune The company's lead drug will enter phase 1 trials, bringing potential good fortune to investors. |
The Motley Fool
December 31, 2011
Brian Orelli |
3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012. |
The Motley Fool
May 6, 2008
Brian Lawler |
MannKind Moves Ahead The pharmaceutical awaits pivotal data on its lead drug Technosphere. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
November 2, 2004
Charly Travers |
Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
The Motley Fool
June 21, 2011
Alexander Crawford |
Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list? |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
October 31, 2011
Brian Orelli |
Gunning for the Leaders Hepatitis C drugs take center stage. |
The Motley Fool
July 1, 2011
Brian Orelli |
What Will Cell Therapeutics Do With Your Money? Unfortunately the answer is probably, "buying a drug." |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
The Motley Fool
August 2, 2004
Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. |
BusinessWeek
February 12, 2007
Gene G. Marcial |
How Access Helps Treat Cancer Access pharmaceuticals is a tiny biotech trading over the counter. But its two cancer drugs are catching the eye of investors. |
The Motley Fool
May 14, 2007
Mike Havrilla |
A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
March 26, 2007
Rich Duprey |
Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note. |
The Motley Fool
October 31, 2006
Brian Lawler |
A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval. |
The Motley Fool
December 31, 2011
David Williamson |
2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here? |
The Motley Fool
April 30, 2008
Brian Lawler |
Alexza Advances 2 More Drugs The pharmaceutical company's compounds keep zipping through clinical trials. |
The Motley Fool
October 31, 2011
Brian Orelli |
5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon... |
The Motley Fool
September 15, 2010
Brian Orelli |
Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out. |
The Motley Fool
June 6, 2006
Brian Lawler |
Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines. |
The Motley Fool
December 31, 2011
Brian Orelli |
3 More Stock-Moving Binary Events to Watch in 2012 There are a lot of drugs that will face binary events in 2012 -- here are three to watch. |
The Motley Fool
April 14, 2008
Brian Lawler |
MannKind Gets Smacked by Big Brother's Bad News Bad news for a competitor sinks MannKind shares. |
The Motley Fool
April 27, 2005
Charly Travers |
Vertex's Emerging Pipeline Early-stage drugs, including one for hepatitis C, are moving forward. For Vertex investors, the phase 2 trials will be the story to watch over the next two years. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
August 11, 2011
Brian Orelli |
Dendreon's a Broken IPO, Again $10 isn't really a magical number. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
The Motley Fool
June 5, 2009
Brian Orelli |
Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients. |
Registered Rep.
February 1, 2005
Bob Hirschfeld |
Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street. |
The Motley Fool
November 25, 2011
Brian Orelli |
7 Black Friday Biotech Bargains Get in at the right time to maximize your returns. |
The Motley Fool
December 5, 2008
Brian Orelli |
Be Kind to MannKind MannKind has good data on its inhaled insulin drug, but will the FDA approve of it and will diabetics buy it? |
The Motley Fool
April 14, 2009
Brian Orelli |
Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge. |
The Motley Fool
June 29, 2011
Brian Orelli |
So Much Insulin, So Little Use for It MannKind settles its supply agreement with Merck. |
The Motley Fool
September 28, 2011
Brian Orelli |
One Step Closer to an FDA Decision Cell Therapeutics is still risky, though. |
